Answers are grounded in this paper and cite their sources.
Neoadjuvant chemoimmunotherapy (NAC + P) improves pathologic complete response (pCR) and survival in early-stage triple-negative breast cancer (TNBC) compared to neoadjuvant chemotherapy (NAC) alone. Real-world recurrence outcomes outside the trial setting remain unclear. This single-institution analysis compared two cohorts of patients with early-stage TNBC treated between July 2009 and April 2023: NAC + P ( n = 344) and NAC ( n = 513). Primary outcomes were local (LR), regional (RR), and distant recurrence (DR); secondary outcomes were DR sites and disease-free survival (DFS). The NAC + P cohort presented with less advanced disease at diagnosis. Overall pCR was higher in NAC + P (58% vs. 36%, p < 0.001). Two-year LR and RR rates did not differ. The 2-year DR rate was nearly halved in NAC + P (9.6% vs. 18%, p < 0.001) and remained lower among patients with residual disease (16% vs. 25%). Two-year brain recurrence was also lower (3.5% vs. 6.6%, p = 0.046). Overall pCR was independently associated with improved DFS in both cohorts, as were immune-related adverse events (irAEs) in NAC + P. In this real-world setting, NAC + P was associated with substantially lower 2-year DR, though the central nervous system remained a common site of recurrence. Beyond pathologic response, the development of irAEs may offer a treatment-specific marker of benefit.
No takes yet. Share an insight, caveat, or question.
Perry et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: